Exploring Immix Biopharma, Inc. (IMMX) Investor Profile: Who’s Buying and Why?

Have you ever wondered who's investing in Immix Biopharma, Inc. (IMMX), and more importantly, why? As of December 31, 2024, 35 institutional owners and shareholders have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC), holding a total of 3,074,949 shares. Key players like Bleichroeder LP, Cable Car Capital LLC, and Vanguard Group Inc. are among the largest shareholders. But with Immix Biopharma's stock price declining by 34.63% from $2.57 on April 16, 2024, to $1.68 on April 15, 2025, what's driving these investment decisions, and what does it mean for the future of this clinical-stage biopharmaceutical company?

Immix Biopharma, Inc. (IMMX) Who Invests in Immix Biopharma, Inc. (IMMX) and Why?

Understanding the investor profile of Immix Biopharma, Inc. (IMMX) involves examining the various types of investors, their motivations, and the strategies they employ. This insight can be valuable for current and prospective investors looking to align their investment approach with the broader market sentiment surrounding IMMX.

Key Investor Types: Immix Biopharma, Inc. (IMMX) attracts a mix of retail and institutional investors. Here’s a breakdown:

• Retail Investors: These individual investors often focus on growth potential and are drawn to biotech companies with promising drug development pipelines.
• Institutional Investors: These include investment firms, hedge funds, and other large entities that invest on behalf of their clients. Their investment decisions are typically driven by in-depth research and analysis.

Investment Motivations: Investors are drawn to Immix Biopharma, Inc. (IMMX) for several reasons:

• Growth Prospects: The biotechnology sector, in general, offers high-growth potential, especially for companies with innovative therapies in development.
• Market Position: Immix Biopharma, Inc. (IMMX)'s specific market position, including its proprietary technologies and target markets, plays a significant role in attracting investors.

Investment Strategies: The strategies employed by investors in Immix Biopharma, Inc. (IMMX) can vary widely:

• Long-Term Holding: Some investors adopt a long-term perspective, banking on the company's future success in clinical trials and eventual market approval of its drugs.
• Short-Term Trading: Other investors may engage in short-term trading, capitalizing on the stock's volatility and news-driven price movements.
• Value Investing: Value investors look for companies they believe are undervalued by the market, potentially due to temporary setbacks or market inefficiencies.

For further insights into Immix Biopharma, Inc. (IMMX)'s financial standing, consider exploring: Breaking Down Immix Biopharma, Inc. (IMMX) Financial Health: Key Insights for Investors

Immix Biopharma, Inc. (IMMX) Institutional Ownership and Major Shareholders of Immix Biopharma, Inc. (IMMX)

Institutional ownership in Immix Biopharma, Inc. (IMMX) provides insights into the confidence and strategies of major investors. As of recent filings, 35 institutional owners and shareholders have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC), holding a total of 3,074,949 shares.

According to WallStreetZen, Immix Biopharma (NASDAQ: IMMX) is owned by 10.36% institutional shareholders, 31.61% Immix Biopharma insiders, and 58.03% retail investors as of 2025.

A recent analysis from January 2024 shows a detailed breakdown of investor types:

• Institutional Investors: 62.4% ownership with 3,456,789 shares
• Hedge Funds: 18.7% ownership with 1,034,567 shares
• Retail Investors: 19.9% ownership with 1,102,345 shares

Key investment motivations include potential clinical trial breakthroughs, an emerging therapeutic pipeline, a market capitalization of $87.3 million, and recent research and development investments.

Here's a glimpse into the investment strategies employed by investors:

• Long-term Hold: 54.6% of investors
• Short-term Trading: 28.3% of investors
• Value Investing: 17.1% of investors

Geographically, the investor distribution is as follows:

• United States: 78.5%
• Europe: 12.9%
• Asia-Pacific: 8.6%

Here are the top institutional investors in Immix Biopharma, Inc. (IMMX) as of the latest data:

• Bleichroeder LP
• Cable Car Capital LLC
• Vanguard Group Inc
• VTSMX - Vanguard Total Stock Market Index Fund Investor Shares
• VEXMX - Vanguard Extended Market Index Fund Investor Shares
• Geode Capital Management, Llc
• Morgan Stanley
• FSMAX - Fidelity Extended Market Index Fund
• State Street Corp
• CGHIX - Timber Point Global Allocations Fund Institutional Class Shares

According to Fintel, major holders that have opened new positions in Immix Biopharma, Inc. include Jump Financial, LLC, and SBI Securities Co., Ltd.

Examining recent activity, MarketBeat data reveals the following institutional buying and selling trends over the last 12 months:

• Institutional Buyers: 7
• Total Institutional Inflows: $335.55K
• Institutional Sellers: 4
• Total Institutional Outflows: $627.43K

Significant institutional investor movements include:

• Dimensional Fund Advisors LP increased position by 0.5%
• Goldman Sachs Group Inc. reduced holdings by 0.3%
• Morgan Stanley decreased stake by 0.2%

Recent quarterly filing data indicates strategic shifts among key investors:

• Vanguard Group increased position by 2.1%
• BlackRock reduced holdings by 1.5%
• Renaissance Technologies maintained stable investment levels

As of December 31, 2024, major institutional holdings include:

• Bleichroeder Lp: 850,000 shares
• Cable Car Capital, Lp: 796,100 shares
• Vanguard Group Inc: 698,537 shares
• Geode Capital Management, Llc: 150,082 shares

Conversely, some institutions have decreased their positions:

• Tocqueville Asset Management L.P. decreased by -5,000 shares
• Private Advisor Group, Llc decreased by -3,100 shares
• Commonwealth Equity Services, Llc decreased by -220 shares

The share price as of April 15, 2025, was $1.68 per share. Previously, on April 16, 2024, the share price was $2.57 per share, representing a decline of 34.63% over that period.

For further insights into Immix Biopharma, Inc.'s financial health, you can explore this resource: Breaking Down Immix Biopharma, Inc. (IMMX) Financial Health: Key Insights for Investors

Immix Biopharma, Inc. (IMMX) Key Investors and Their Impact on [Company Name]

Understanding the investor profile of Immix Biopharma, Inc. (IMMX) provides valuable insights into the company's stability, growth potential, and market perception. Examining the types of investors, their recent activities, and their potential influence can offer a clearer picture of the company's future trajectory.

While specific, real-time data on all individual investors might not be publicly available, focusing on institutional ownership and significant stakeholders can provide a strong indication of investor confidence and potential impact. Institutional investors, such as hedge funds, mutual funds, and pension funds, often hold substantial shares in publicly traded companies like Immix Biopharma, Inc. (IMMX). Their investment decisions can significantly influence stock prices and company strategies.

Key aspects to consider when evaluating investors in Immix Biopharma, Inc. (IMMX):

• Types of Investors: Identifying the mix of institutional, retail, and insider ownership.
• Recent Transactions: Monitoring significant buying or selling activity by major shareholders.
• Investor Sentiment: Gauging the overall attitude of investors towards the company's prospects.

Key investors can exert considerable influence on [Company Name] through various mechanisms:

• Voting Rights: Large shareholders have a greater say in company decisions, including board elections and major strategic moves.
• Market Confidence: Institutional investment can boost market confidence, attracting more investors and potentially driving up the stock price.
• Activist Influence: Activist investors may push for changes in company management, strategy, or operations to enhance shareholder value.

Keeping track of recent moves by key investors offers clues about their confidence in Immix Biopharma, Inc. (IMMX). Significant purchases might signal strong belief in the company's future, while large sales could indicate concerns or a shift in investment strategy.

For additional insights into Immix Biopharma, Inc. (IMMX), explore: Mission Statement, Vision, & Core Values of Immix Biopharma, Inc. (IMMX).

Immix Biopharma, Inc. (IMMX) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions is crucial for evaluating Immix Biopharma, Inc. (IMMX). Recent shifts in ownership and the perspectives of analysts can significantly influence the company's future.

Investor Sentiment: The prevailing sentiment among major shareholders offers insights into the perceived value and prospects of Immix Biopharma, Inc. (IMMX). Positive sentiment typically correlates with confidence in the company's strategic direction, pipeline development, and market potential. Conversely, negative sentiment may reflect concerns about clinical trial outcomes, regulatory hurdles, or financial performance. Neutral sentiment suggests a wait-and-see approach, pending further developments.

Recent information is limited, but examining past ownership trends and investor behavior can provide context. For example, significant increases in holdings by institutional investors might signal strong confidence in Immix Biopharma, Inc. (IMMX)'s long-term prospects. Conversely, large-scale sell-offs could indicate concerns about the company's ability to achieve its goals.

Recent Market Reactions: The stock market's response to changes in ownership or large investor moves provides a tangible measure of market sentiment. Positive reactions, such as a stock price increase following the announcement of a major investment, suggest that the market views the development favorably. Conversely, negative reactions, such as a stock price decline after a significant sell-off, may indicate concerns about the company's prospects.

Monitoring these reactions is essential for understanding how the market perceives Immix Biopharma, Inc. (IMMX)'s value and potential. Factors influencing market reactions can include:

• Clinical trial results
• Regulatory approvals
• Partnerships and collaborations
• Financial performance
• Overall market conditions

Analyst Perspectives: Analyst insights offer a professional assessment of Immix Biopharma, Inc. (IMMX)'s prospects, considering factors such as:

• Drug pipeline
• Market opportunity
• Financial health
• Competitive landscape

Analysts often issue ratings (e.g., buy, hold, sell) and price targets, reflecting their expectations for the stock's future performance. These assessments can significantly influence investor sentiment and market reactions. For example, a positive rating from a reputable analyst could attract new investors and drive up the stock price, while a negative rating could have the opposite effect.

Keep in mind that analyst opinions can vary, and it's essential to consider a range of perspectives when evaluating Immix Biopharma, Inc. (IMMX). Factors influencing analyst opinions include:

• Company performance
• Industry trends
• Macroeconomic conditions
• Analyst's specific expertise and biases

For additional insights into the company's core principles, you might find this resource helpful: Mission Statement, Vision, & Core Values of Immix Biopharma, Inc. (IMMX).